Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$462M |
| 2 |
AGN
Allergan plc
AGN
|
+$390M |
| 3 |
AT&T
T
|
+$371M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$353M |
| 5 |
NextEra Energy
NEE
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.97B |
| 2 |
Meta Platforms (Facebook)
META
|
+$435M |
| 3 |
Pfizer
PFE
|
+$377M |
| 4 |
GE Aerospace
GE
|
+$354M |
| 5 |
Starbucks
SBUX
|
+$323M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.71% |
| 3 | Consumer Staples | 9.79% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$126B
| $3.68B | 3.57% |
65,992,111
+5,781,450
| +10% | +$353M |
|
|
NVO
2
Novo Nordisk
NVO
$213B
| $1.68B | 1.63% |
55,720,452
+3,286,400
| +6% | +$97.9M |
|
3
Vertex Pharmaceuticals
VRTX
$120B
| $1.63B | 1.59% |
6,859,682
-216,900
| -3% | -$49.8M |
|
4
VeriSign
VRSN
$23.8B
| $1.46B | 1.42% |
8,105,290
-165,400
| -2% | -$32.5M |
|
5
Biogen
BIIB
$29.6B
| $1.42B | 1.37% |
4,473,912
-95,994
| -2% | -$29.1M |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $1.26B | 1.22% |
7,089,144
+2,069,332
| +41% | +$390M |
|
7
Chipotle Mexican Grill
CMG
$41.1B
| $1.2B | 1.17% |
91,962,100
+3,785,000
| +4% | +$59.8M |
|
8
Walmart Inc
WMT
$863B
| $1.11B | 1.08% |
29,406,642
+2,626,131
| +10% | +$101M |
|
9
Humana
HUM
$47.4B
| $1.11B | 1.08% |
3,529,142
+577,900
| +20% | +$195M |
|
10
AbbVie
ABBV
$454B
| $1.03B | 1% |
13,555,849
+1,759,105
| +15% | +$150M |
|
11
Gilead Sciences
GILD
$162B
| $937M | 0.91% |
12,531,209
-4,431,735
| -26% | -$306M |
|
12
Palo Alto Networks
PANW
$265B
| $889M | 0.86% |
32,516,106
-1,458,600
| -4% | -$50.9M |
|
13
Atlassian
TEAM
$20.3B
| $883M | 0.86% |
6,434,024
+352,100
| +6% | +$49.2M |
|
14
GSK
GSK
$102B
| $874M | 0.85% |
18,461,163
+3,239,084
| +21% | +$173M |
|
15
Monster Beverage
MNST
$91.5B
| $766M | 0.74% |
27,213,184
+4,308,554
| +19% | +$138M |
|
16
Amgen
AMGN
$201B
| $760M | 0.74% |
3,750,003
+590,465
| +19% | +$129M |
|
17
Novartis
NVS
$297B
| $700M | 0.68% |
8,491,408
+1,890,226
| +29% | +$169M |
|
18
Hershey
HSY
$34.9B
| $696M | 0.68% |
5,255,138
+764,076
| +17% | +$113M |
|
|
S
19
DELISTED
Sprint Corporation
S
| $675M | 0.66% |
78,342,305
-11,711,655
| -13% | -$82.2M |
|
20
Target
TGT
$61.1B
| $652M | 0.63% |
7,009,159
+1,337,191
| +24% | +$148M |
|
21
Domino's
DPZ
$10.7B
| $642M | 0.62% |
1,981,525
+275,425
| +16% | +$85M |
|
22
Fortinet
FTNT
$111B
| $614M | 0.6% |
30,321,940
+1,567,500
| +5% | +$33.6M |
|
23
Molina Healthcare
MOH
$10.5B
| $580M | 0.56% |
4,148,109
-23,400
| -0.6% | -$3.13M |
|
|
24
Baidu
BIDU
$36.5B
| $576M | 0.56% |
5,710,043
+3,793,066
| +198% | +$462M |
|
25
Duke Energy
DUK
$101B
| $573M | 0.56% |
7,078,432
+837,779
| +13% | +$77M |
|
Similar funds
Renaissance Technologies's Q1 2020 Portfolio in Review
As of Q1 2020, Renaissance Technologies held 4,047 positions worth $103B, down 21% from $130B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Renaissance Technologies's Q1 2020 filing shows 573 new, 1,474 increased, 1,328 reduced and 645 closed positions. Its largest new stake was AT&T: 13,563,699 shares worth $299M. The largest sale was Tesla, an estimated $1.97B.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Staples.
- Renaissance Technologies's largest Q1 2020 buy was AT&T: 13,563,699 shares worth $299M.
- Renaissance Technologies added most to Baidu in Q1 2020, an estimated $462M increase.
- Renaissance Technologies's biggest Q1 2020 reduction was Tesla, cutting an estimated $1.97B.
- Renaissance Technologies fully exited Phillips 66 in Q1 2020, selling an estimated $214M.
- Renaissance Technologies's ten largest holdings make up 15% of its $103B portfolio in Q1 2020.
- Renaissance Technologies opened 573 new positions and closed 645 in Q1 2020.
- Renaissance Technologies's portfolio value fell 21% quarter-over-quarter to $103B.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.